25th Jul 2014 11:31
LONDON (Alliance News) - Advanced Oncotherapy PLC said Friday that the Food and Drug Administration approval process for its LIGHT cancer treatment technology is expected to be completed with the next 15 months, according to its product development committee, in a statement ahead of its annual general meeting.
The medical technology company said that its pipeline of prospective clients is growing, and it has identified additional locations including two in South East Asia, three in the Middle East and two in North America.
The LIGHT radiotherapy system is based around technology Advanced Oncotherapy acquired in 2013 from ADAM SA, a spin-off company from the European Organization for Nuclear Research, known as CERN, in Geneva. The technology produces a proton beam that can be used to treat cancer.
The company said that the delivery timescale for a key radio frequency quadripole unit from CERN has been accelerated. The unit acts as an injector to subsequent parts of the accelerator of the proton beam.
Shares in Advanced Oncotherapy were trading up 0.3% at 3.46 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
AVO.L